These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27023049)

  • 1. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Melanoma therapeutic escape: the biomechanical track].
    Lecacheur M; Girard CA; Deckert M; Tartare-Deckert S
    Med Sci (Paris); 2020 Nov; 36(11):961-965. PubMed ID: 33151853
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.
    Roesch A
    Oncogene; 2015 Jun; 34(23):2951-7. PubMed ID: 25109330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Many ways to resistance: How melanoma cells evade targeted therapies.
    Kozar I; Margue C; Rothengatter S; Haan C; Kreis S
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):313-322. PubMed ID: 30776401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Plasticity and Resistance to Immunotherapy.
    Horn LA; Fousek K; Palena C
    Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma stem cells.
    Roesch A
    J Dtsch Dermatol Ges; 2015 Feb; 13(2):118-24. PubMed ID: 25631128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The great escape: tumour cell plasticity in resistance to targeted therapy.
    Boumahdi S; de Sauvage FJ
    Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Hölzel M; Bovier A; Tüting T
    Nat Rev Cancer; 2013 May; 13(5):365-76. PubMed ID: 23535846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Gide TN; Wilmott JS; Scolyer RA; Long GV
    Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
    Hossain SM; Eccles MR
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
    Long KB; Collier AI; Beatty GL
    Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity.
    Terry S; Faouzi Zaarour R; Hassan Venkatesh G; Francis A; El-Sayed W; Buart S; Bravo P; Thiery J; Chouaib S
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
    Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
    Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
    Benboubker V; Boivin F; Dalle S; Caramel J
    Front Immunol; 2022; 13():873116. PubMed ID: 35432344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do tumor stem cells actively escape from host immunosurveillance?
    Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
    Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Tumor Microenvironment on Immune Escape of Melanoma.
    Simiczyjew A; Dratkiewicz E; Mazurkiewicz J; Ziętek M; Matkowski R; Nowak D
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory regulation of stem-like cells in melanoma.
    Lim MS; Wang JH; Power DG; Redmond HP
    Melanoma Res; 2017 Feb; 27(1):1-7. PubMed ID: 27764061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review.
    Kyriakou G; Melachrinou M
    Future Oncol; 2020 Jul; 16(21):1549-1567. PubMed ID: 32484008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.
    Ferguson LP; Diaz E; Reya T
    Trends Cancer; 2021 Jul; 7(7):624-634. PubMed ID: 33509688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.